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Abstract
Background: FUS1/TUSC2 is a novel tumor suppressor located in the critical 3p21.3 chromosomal region frequently
deleted in multiple cancers. We previously showed that Tusc2-deficient mice display a complex immuno-inflammatory
phenotype with a predisposition to cancer. The goal of this study was to analyze possible involvement of TUSC2 in
malignant pleural mesothelioma (MPM) - an aggressive inflammatory cancer associated with exposure to asbestos.
Methods: TUSC2 insufficiency in clinical specimens of MPM was assessed via RT-PCR (mRNA level), Representational
Oligonucleotide Microarray Analysis (DNA level), and immunohistochemical evaluation (protein level). A possible link
between TUSC2 expression and exposure to asbestos was studied using asbestos-treated mesothelial cells and ROS
(reactive oxygen species) scavengers. Transcripional effects of TUSC2 in MPM were assessed through expression array
analysis of TUSC2-transfected MPM cells.
Results: Expression of TUSC2 was downregulated in ~84% of MM specimens while loss of TUSC2-containing 3p21.3
region observed in ~36% of MPMs including stage 1 tumors. Exposure to asbestos led to a transcriptional suppression
of TUSC2, which we found to be ROS-dependent. Expression array studies showed that TUSC2 activates transcription
of multiple genes with tumor suppressor properties and down-regulates pro-tumorigenic genes, thus supporting its role
as a tumor suppressor. In agreement with our knockout model, TUSC2 up-regulated IL-15 and also modulated more
than 40 other genes (~20% of total TUSC2-affected genes) associated with immune system. Among these genes, we
identified CD24 and CD274, key immunoreceptors that regulate immunogenic T and B cells and play important roles in
systemic autoimmune diseases. Finally, clinical significance of TUSC2 transcriptional effects was validated on the
expression array data produced previously on clinical specimens of MPM. In this analysis, 42 TUSC2 targets proved to
be concordantly modulated in MM serving as disease discriminators.
Conclusion:  Our data support immuno-therapeutic potential of TUSC2, define its targets, and underscore its
importance as a transcriptional stimulator of anti-tumorigenic pathways.
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Background
Malignant Mesothelioma (MPM) is one of the most
aggressive and devastating tumors, with a median survival
of 10-12 months. MPM is a highly proliferative and
locally invasive cancer that rapidly engulfs the pleural cav-
ity, destroys normal lung structure, and results in cardiop-
ulmonary compromise and progressive pain [1]. It is
estimated that more than 90% of MPM cases are linked
with exposure to asbestos [2]. Lodged asbestos fibers irri-
tate mesothelial or pulmonary tissue causing chronic
inflammation, and in the thorax, this persistent inflam-
mation may eventually result in MPM or lung cancer [3].
Treatment of MPM with conventional therapies has
proven to be largely unsuccessful [4]. Being an intrinsi-
cally drug resistant tumor, MPM shows only partial
response to a combination of pemetrexed (Alimta) and
cisplatin in ~41% of patients [5]. Animal studies, how-
ever, have demonstrated that MPM may respond to
immunotherapy [6-8]. Thus, there is an urgent need to
develop new effective therapies based on the knowledge
of the key immunoregulatory molecules that could poten-
tially suppress MPM growth.
Tumor suppressor genes (TSGs) play a major role in the
pathogenesis of human cancers. Recurrent loss of hetero-
zygosity in the 3p21.3 chromosomal region, as well as
homozygous deletions and epigenetic inactivation of this
area are observed in early stages of lung, breast, ovarian,
liver, cervical, and other cancers suggesting a critical role
for one or more genes that reside in 3p21.3. The products
of these genes may act as "gatekeepers" in the molecular
pathogenesis of common epithelial cancers [9-14].
FUS1 (TUSC2) was first characterized by us as a gene
located in the minimal ~120 kb common area of loss in
3p21.3. The TUSC2 gene product is a small, basic, soluble,
globular, and highly conserved protein, which is
expressed in a variety of cell types. We have demonstrated
that the TUSC2 protein resides mostly in mitochondria
[15]. The high expression of Tusc2 during mouse embryo-
genesis and, specifically, in mouse embryonic stem cells
(ESC) http://www.ncbi.nlm.nih.gov/sites/entrez suggests
that TUSC2 has the potential as a cancer-causing gene. The
tumor suppressor property of TUSC2 was confirmed
experimentally [16-19] on lung cancer cell lines in vitro
and on xenograft mice in vivo. Intratumoral and intrave-
nous injections of TUSC2 into mice bearing xenografted
A549 lung cancer resulted in significant inhibition of
tumor growth and metastases. The biological function of
the TUSC2 protein, however, is unknown and little data
exist on the TUSC2-dependent signal transduction path-
ways. Most recently, TUSC2 was associated with the c-Abl/
p53 pathway [20,21]. It has also been demonstrated that
exogenous expression of TUSC2 using a nanoparticle-
mediated gene transfer technique sensitizes NSCLC cells
to cisplatin, resulting in a 4- to 6-fold increase in the
TUSC2 tumor suppressor activity. The effect of TUSC2 on
chemosensitivity was associated with down-regulation of
MDM2, accumulation of p53, and activation of the Apaf-
1 apoptotic pathway [22].
We have recently demonstrated that genetically modified
mice lacking one or both copies of the Tusc2 gene develop
an autoimmune disorder with an inflammatory back-
ground, and produce tumors at the sites of chronic
inflammation [15]. These findings prompted us to inves-
tigate possible involvement of TUSC2 in human inflam-
matory cancers. Since MPM is one of the malignancies
clearly linked to chronic inflammation induced by asbes-
tos, we asked whether TUSC2 deficiency could be
observed in clinical specimens of MPM at the DNA,
mRNA and protein levels. In order to analyze the possible
mechanisms of TUSC2 expression modulation, we stud-
ied genomic copy number variation in the TUSC2 locus
using Representational Oligonucleotide Microarray Anal-
ysis (ROMA) and investigated a possible link between
asbestos exposure and this gene expression. To better
understand the role of TUSC2 in MPM, we performed
Affymetrix microarray profiling of MPM cells transfected
with the TUSC2 transgene and correlated these data with
previously produced microarray profiles of clinical speci-
mens of MPM to identify clinically relevant TUSC2 tar-
gets.
Results
Expression of TUSC2 mRNA is down-regulated in a large 
proportion of MPM tumors
To find out whether TUSC2 mRNA expression is modu-
lated in MPM we analyzed its expression in tumors of dif-
ferent histology, stage, and clinical behavior by semi-
quantitative RT-PCR. For this study, we used a set of 30
matched specimens of unaffected peritoneum and MPM
tumors. We found that TUSC2 is down-regulated in ~83%
(25 out of 30) of MPMs as compared to matched normal
mesothelium (see representative panel in Fig. 1A). We
demonstrated as well that TUSC2 expression is independ-
ent of the disease histology and stage (data not shown)
suggesting that TUSC2 down-regulation may be an early
event in mesothelioma development.
Down-regulation of the TUSC2 protein in MPM specimens
Our set of MPM specimens used for immunohistochemi-
cal studies included epithelial, sarcomatoid, and mixed
(biphasic) histological types. We used specific anti-TUSC2
antibodies successfully tested previously on a set of
human lung cancer samples [19]. We pooled the sarcoma-
toid and biphasic tumors in one group based on their
common sarcomatoid component (Table 1). The TUSC2
protein was localized in the cytoplasm of tumor cells.
Overall, ~88% (53 out of 60) of epithelial and ~80% (36Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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Down-regulation of TUSC2 expression inmesothelioma Figure 1
Down-regulation of TUSC2 expression in mesothelioma. A. TUSC2 mRNA levels are decreased in the majority of 
mesotheliomas. Semi-quantitative RT-PCR analysis of RNA isolated from matched normal and tumor specimens derived from 
mesothelioma patients. Upper panel (reproduced from [23]) displays RT-PCR products obtained with TUSC2-specific primers; 
bottom panel represents a loading control - RT-PCR products with the primers specific for PPIA, an invariantly expressed 
gene. N- normal tissue, T- tumor. Numbers at top represent disease stages, numbers at bottom show normalized fold change. 
B. Representative examples of TUSC2 immunohistochemical staining of mesothelioma and normal peritoneum. Intensity levels 
of TUSC2 staining designated as, 3+, 2+ and 1+ are illustrated by representative images. C. Loss of the 3p21.3 chromosomal 
area in mesothelioma tumor specimens as identified by ROMA. Synoptic map of DNA copy number variation in chromosome 
3 in mesotheliomas (FDR = 0.09). Arrow shows the site of recurrent loss of TUSC2-containing 3p21.3 region in mesothelioma 
patients (n = 22). D. Detailed view of the 3p21.3 region losses in different mesothelioma patients and identification of common 
deletion area. Green boxes represent deletions detected in patients diagnosed with different stages of mesothelioma while red 
sector show gains. Coded patient IDs are shown in the left and disease stages in the right.
Table 1: Immunohistochemical study of TUSC2 expression in MPMs.
Histology of tumors No. of samples TUSC2 score,
mean (SD)
Low (0-100),
n (%)
Intermediate (101-220)
n (%)
High (221-300)
n (%)
Epithelial 60 157.3 (66) 11 (18) 42 (70) 7 (12)
Biphasic+sarcomatoid 45 172.7 (56) 6 (13) 30(67) 9 (20)Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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out of 45) of biphasic/sarcomatoid MPMs showed low or
intermediate levels of TUSC2 expression (S1). We noted
that the difference between the epithelial and sarcoma-
toid/biphasic types was not statistically significant (p =
0.09). Overall, MPM specimens showed lower scores and
levels of TUSC2 expression as compared to normal mes-
othelium that was scored at a 280-300 intensity level (Fig.
1B). Specifically, most MPM tumors including stage I (89
out of 105, ~85%) had a score of < 220, which was never
associated with normal mesothelial tissue pointing to
down-regulation of the TUSC2 protein in MPM. As above,
no correlation with the stage was observed.
The TUSC2 locus is frequently deleted in MPM tumors
Decreased TUSC2 expression in ~83% of MPMs prompted
us to seek possible mechanism(s) of its down-regulation.
DNA copy number alteration (CNA) data generated previ-
ously by ROMA on 22 MPM specimens compared with
normal human DNA isolated from fibroblasts [23] were
processed using the ACE (analysis of copy errors) algo-
rithm available from CGH-Explorer [24], and plotted
across chromosome 3 (Fig. 1C). We found that a ~1.5-6
Mb TUSC2-containing 3p21.3 region was under-repre-
sented in 8 out of 22 samples analyzed (~36%) and iden-
tified the boundaries of the characterized deletions in
individual patients (Fig. 1D). Analysis of different tumor
stages implied that the 3p21.3 deletion in MM is a fre-
quent event in stages 2 and 3 but could also be detected as
early as stage 1 (one out of five stage 1 patients studied
showed the deletion).
TUSC2 expression is decreased upon asbestos exposure
While TUSC2 allelic loss documented in ~36% of MPM
patients is an important observation, it is not sufficient to
explain the fact that up to ~83% of analyzed MPMs
showed a decrease in the TUSC2 mRNA level. Since MPM
is an asbestos-induced malignancy of the mesothelial
layer, we hypothesized that TUSC2 expression could be
modulated in normal mesothelial cells by asbestos expo-
sure. We treated Met5A and primary peritoneal mesothe-
lial cells with asbestos and analyzed TUSC2 level by semi-
quantitative RT-PCR. Invariably expressed PPIA was used
as a loading control. We found that TUSC2 was down-reg-
ulated by asbestos (Fig. 2A, bar 2) in both types of mes-
othelial cells suggesting that one of the stimuli that may
cause TUSC2 decrease in MPM is exposure to asbestos.
ROS scavengers prevent asbestos-induced TUSC2 
downregulation
Studies on animal models and cell cultures confirmed
that asbestos fibers generate reactive oxygen species (ROS)
[25]. Hence, we asked if the observed asbestos-dependent
TUSC2 suppression was due to asbestos-generated ROS.
Pretreatment of the cells with catalase (a specific H2O2
scavenger) or superoxide dismutase SOD (a specific super-
oxide anion O2
- scavenger) negated TUSC2 downregula-
tion (Fig 2B, bars 3 and 4). The results of these
experiments provide a link between asbestos exposure,
asbestos-generated ROS, and modulation of TUSC2
expression in mesothelial cells.
Transcriptional changes triggered by TUSC2 
overexpression in mesothelioma cells
We previously demonstrated on the mouse model that
TUSC2 may affect mRNA levels of certain genes, such as
IL15 [15]. To provide insight into the molecular basis of
putative TUSC2 tumor suppressor activity in MPM and
perform genome-wide analysis of TUSC2 transcriptional
effects, we took advantage of human epithelioid MPM
H2595 cells produced in our laboratory [26]. Since
TUSC2 is commonly suppressed in MPM (see above) we
used forced expression of TUSC2 to identify its targets.
Analysis of these microarray data produced 228 probes
corresponding to 195 genes modulated at least 2-fold by
TUSC2 as compared to empty vector-transfected H2595
cells. We then performed biological profiling of TUSC2
targets using Xenobase software [27] for hypergeometric
analysis of Gene Ontology annotation http://www.gene
ontology.org/. These analyses identified groups of genes
involved in organization of chromatin structure, cell dif-
ferentiation, cell cycle, and immune system regulation
(Table 2). Other statistically significant GO groups
included 'intra-and inter-cellular signaling', 'molecular
synthesis and metabolism', and 'homeostasis and secre-
tion' categories. These findings suggest that TUSC2 activi-
ties may be related to vital cellular processes that are
commonly affected during malignant transformation.
Using NCBI annotation we then identified among the
TUSC2 targets multiple genes previously associated with
tumorigenesis (Table 3). Consistent with the TUSC2
tumor suppressor role, 21 genes with anti-tumorigenic
properties including BCL211, FOXN3, GAS1, and NME5
were up-regulated by TUSC2. On the other hand, 20 pro-
tumorigenic factors with JUN, ETS1, MALAT1, ATF3, and
LOX among them were down-regulated. These microarray
data were validated by semi-quantitative RT-PCR on sev-
eral genes representing different functional groups
(Fig. 3A).
To validate these TUSC2-dependent transcriptional
changes we overexpressed TUSC2 in four additional MPM
cell lines and performed RT-PCR evaluation of several
potential TUSC2 targets. Despite high intra-individual
variation typical for mesothelioma [24] we were able to
confirm all seven gene-candidates in at least two cell lines
(Fig. 3B). Moreover, expression of SKIL, a negative regula-
tor of TGF-beta signaling [28], and EGR1, a potent tran-
scription factor with a dual role in tumorigenesis [29], was
modulated upon TUSC2 introduction in 4 out of 5 tested
MPM cell lines.Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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To assess clinical significance of newly identified TUSC2
targets we used our previously produced MPM expression
array data set (30 MPM and 7 control specimens) and
found that more then 21 genes down-regulated by TUSC2
in H2595 were up-regulated in clinical specimens of MPM
and, vise versa, 24 genes up-regulated by TUSC2 in H2595
were suppressed in MPM with significant p-values (Fig. 4A
and Table 4). The plots that illustrate expression of some
of these genes in MPM are shown in Fig. 4B and 4C. Over-
all, these data imply that up to ~23% of cancer-associated
TUSC2 targets may contribute to MPM progression and
serve in future as novel therapeutic targets.
Our previous data produced on Tusc2 KO mice suggested
that TUSC2 is an important regulatory component of
immune system, which is able to stimulate IL-15 expres-
sion as well as maturation of NK cells and lymphocytes
[15]. In agreement with the mouse KO data, one of the
multiple targets modulated by TUSC2 in MPM cells was
IL15 that was 2-fold up-regulated by FUS1 introduction.
Other genes previously associated with the immune sys-
tem included IL11 (4-fold down-regulated by TUSC2),
CD24 and CD274 (Table 3), CD54/ICAM1 (2-fold up-
regulated by FUS1) as well as ~2-3-fold up-regulated com-
plement components C1s, CFB, and C3 (Table 4). To fur-
ther explore the immune link of TUSC2 we took
advantage of the BioGPS portal developed by the Novartis
Research Institute https://biogps.gnf.org/. This analysis
identified among TUSC2 targets 46 human genes that
show exceptionally high levels of expression in immune
cells (Table 5). Noteworthy, expression of most of them
(marked with asterisks) was specific to immune tissues
TUSC2 expression is regulated by asbestos and reactive oxygen species Figure 2
TUSC2 expression is regulated by asbestos and reactive oxygen species. A. TUSC2 is down-regulated by asbestos in 
mesothelial cell line Met5A and healthy primary culture of mesothelial cells. 1 - non-treated cells; 2 - cells treated with 2.5 μg/
cm2 crocidolite asbestos. B. TUSC2 suppression by asbestos is restored upon pre-incubation with reactive oxygen species 
(ROS) scavengers. Pre-treatment of cells with 500 U/mL catalase (bar 3) or 250 U/mL superoxide dismutase, (SOD) (bar 4) for 
30' prior to addition of asbestos to Met5A cells. Data were obtained in triplicates via semi-quantitative RT-PCR and are 
expressed in percentage change from control (non-treated cells).Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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and cells and seemed to be dependent on the activation
status and cell type. At this time, the function of many of
these genes is not yet known. Overall, our results imply
that TUSC2 plays critical roles in cell cycle progression,
cell differentiation, and immune system regulation, and
that its downstream targets may provide important
insights previously unknown molecular mechanisms and
pathways involved in cellular defense against cancer.
TUSC2 similarity to the IRF7 DNA-binding domain
Prominent transcriptional effects triggered by TUSC2
over-expression in MPM suggested that it may function as
an essential transcriptional regulator. In this study, we
therefore analyzed in more detail the similarity between
the TUSC2 and IRF7 proteins that we reported previously
[15]. As shown in Fig. 5A, the N-terminus of TUSC2 dis-
plays similarity with the DNA-binding domain of IRF7.
Multiple alignment performed within the IRF family
using TCoffee http://www.tcoffee.org/ helped us to iden-
tify evolutionary conserved amino acid residues in this
domain. Noteworthy, most of the TUSC2 amino acid res-
idues in this area follow the functional conservation pat-
tern including the only invariable residue Arg96 (shown
with asterisk in Fig. 5A). The similarity with the IRF7
DNA-binding domain is consistent with the observed
TUSC2 effects on immune genes. In addition, our in silico
analysis confirmed the presence of IRF and NF-kB-binding
sites in the promoters of newly identified TUSC2 targets
(data not shown). Mutational analysis of the putative
DNA-binding TUSC2 domain is required, however, to
answer if TUSC2 is a bone fide transcriptional regulator.
Discussion
TUSC2 resides in the critical ~120 kb region that is often
deleted in lung, breast, head and neck, renal, and other
cancers [10]. While studies on lung cancer cell lines
revealed a limited (~4%) frequency of mutations in the
TUSC2 gene [10,16] and infrequent methylation of its
promoter [16], large-scale analysis of TUSC2 expression in
lung cancers and in bronchial squamous metaplastic and
dysplastic lesions have revealed significantly lower levels
of TUSC2 as compared to normal hyperplastic epithelia
[30]. These data suggest that TUSC2 down-regulation may
play an important role in early pathogenesis of lung can-
cer.
Targeted disruption of the Tusc2 gene in mice that our
group performed previously resulted in a complex immu-
nological autoimmune phenotype with an inflammatory
background and recurrent tumorigenesis at the sites of
chronic inflammation [15]. Based on these data, we
hypothesized that TUSC2 down-regulation may contrib-
ute to the development of human cancers associated with
chronic inflammation. One such cancer is mesothelioma,
an aggressive and mostly lethal malignancy linked with
asbestos exposure. Our analysis of the TUSC2 mRNA and
protein levels in MPM as compared to normal peritoneum
confirmed the decrease in TUSC2 level in ~84% of tumors
irrespective of stage and histological type. This observa-
Table 2: TUSC2 target genes grouped based on involvement in biological processes.
Chromatin structure P value Cell cycle P value
nucleosome assembly 1.31E-06 cell growth and/or maintenance 0.0001
chromosome organization 1.97E-06 regulation of mitotic cell cycle 0.04
negative regulation of histone acetylation 0.007 cell cycle arrest 0.05
nucleosome disassembly 0.04 negative regulation of S phase 0.04
imprinting 0.04 negative regulation of cell proliferation 0.02
Cell differentiation P value Immune system related activities P value
adipocyte differentiation 0.0008 complement activation 0.001
megakaryocyte differentiation 0.007 immune response 0.005
cell differentiation 0.01 antigen processing 0.007
Intra-and inter-cellular signaling P value innate immune response 0.02
cell-cell signaling 0.02 humoral immune response 0.04
cell surface receptor linked signal transduction 0.04 response to reactive oxygen species 0.01
regulation of G-pr. coupled receptor pr. signaling pathway 0.05 Synthesis and metabolism P value
Other proceses P value glycolipid biosynthesis 0.02
viral assembly, maturation, and release 0.02 cAMP metabolism 0.02
lactation 0.04 valine metabolism 0.02
blood coagulation 0.04 regulation of hormone biosynthesis 0.03
transcription from Pol II promoter 0.04 nucleotide catabolism 0.03
Homeostasis and secretion P value proteoglycan metabolism 0.04
growth hormone secretion 0.02
calcium ion homeostasis 0.03
insulin secretion 0.04
Hypergeometric P-values define probability of involvement of potential TUSC2 in listed biological processes. Only statistically significant (p ≤ 0.05) 
associations are shown.Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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Table 3: List of anti-tumorigenic and pro-tumorigenic molecules modulated by introduction of TUSC2 in H2595 MPM cell line 
(expression array data).
Anti-tumorigenic molecules
up-regulated by TUSC2
Fold
change
Pro-tumorigenic molecules
suppressed by TUSC2
Fold change
ALDH6A1, aldehyde dehydrogenase 6 family +2.5 ATF3, activating transcription factor 3 -2.7
APOL6, apolipoprotein L, 6 +2.0 CD24, CD24 molecule -3.1
BCL2L11, BCL2-like 11 (apoptosis facilitator) +2.0 CD274, CD274 antigen; programmed cell death 1 ligand 1 -6.2
CCDC98, coiled-coil domain containing 98 +2.3 CTGF, connective tissue growth factor -2.0
CCNG2, cyclin G2 +2.5 EFNB2, ephrin-B2 -2.0
EGR1, early growth response 1 +2.4 GPR87, G protein-coupled receptor 87 -2.3
EXT1, exostoses (multiple) 1 +2.1 ELK4, ETS-domain protein (SRF accessory protein 1) -2.2
FBXO4, F-box protein 4 +2.1 JUN, jun oncogene -2.5
FOXN3, forkhead box N3 +2.6 IL11, interleukin 11 -3.9
GAS1, growth arrest-specific 1 +2.1 LOX, lysyl oxidase -3.0
MCC, mutated in colorectal cancers +2.1 MALAT1, metastasis associated lung adenocarcinoma 
transcript 1
-2.5
MLL5, myeloid/lymphoid or mixed-lineage leukemia 5 +2.5 MIHG1, microRNA host gene -2.6
NME5, non-metastatic cells 5 +2.4 PLAU, plasminogen activator, urokinase -3.2
RARRES1, retinoic acid receptor responder (tazarotene 
induced) 1
+4.1 PLAUR, plasminogen activator, urokinase receptor -2.1
RARRES3, retinoic acid receptor responder (tazarotene 
induced) 3
+2.8 RGS4, regulator of G-protein signaling 4 -4.3
SELENBP1, selenium binding protein 1 +2.1 SET, SET translocation (myeloid leukemia-associated) -2.2
SIDT2, SID1 transmembrane family, member 2 +2.3 SKIL, SKI-like oncogene -2.3
SAMD9L, sterile alpha motif domain containing 9-like +2.0 THBS1, thrombospondin 1 -2.5
TNS1, tensin 1 +2.5 B4GALT1, UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase
-2.5
WFDC2, WAP four-disulfide core domain 2 +3.5 ETS1, v-ets erythroblastosis virus E26 oncogene -2.3
WSB1, WD repeat and SOCS box-containing 1 +2.0Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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RT-PCR validation of TUSC2-dependent changes in H2595  for selected genes Figure 3
RT-PCR validation of TUSC2-dependent changes in 
H2595 for selected genes. A. Semi-quantitative RT-PCR 
analysis was done on RNA specimens used for Affymetrix 
profiling. Fold-estimation of up- (+) or down- (-)-regulation 
for each gene are shown in brackets. Invariably expressed 
PPIA gene served as a loading control. B. TUSC2 transcrip-
tional targets were confirmed by semi-quantitative RT-PCR 
in four additional mesothelioma cell lines. TUSC2-dependent 
transcriptional change is shown as 'up' or 'down'; '0' indicates 
that PCR product was not detected.
tion suggests a fundamental importance of TUSC2 down-
regulation for MPM origin and progression. Incomplete
TUSC2 down-regulation shown in our study is consistent
with the haploinsufficient effect of the gene observed in
our mouse KO model. Indeed, mice hetero- or
homozygous on the Tusc2 deletion shared similar immu-
nological and tumorigenic phenotypes at comparable fre-
quencies. These data suggest that even partial loss of the
TUSC2 dosage is sufficient to trigger pathological inflam-
mation and increase susceptibility to cancer [15].
We considered several possible scenarios of TUSC2 inacti-
vation in MPM. Since importance of LOH in the TUSC2
chromosomal area had been demonstrated for multiple
cancers [10,16], we performed analysis of DNA copy
number variation in the 3p21.3 region in MPM tumors.
We found that deletion of the TUSC2 locus is a recurrent
event in MPMs (~36%) substantiating the idea of LOH as
a principal and clinically relevant mechanism of TUSC2
inactivation in MPM.
We then hypothesized that down-regulation of TUSC2
expression may be also triggered by carcinogenic stimuli.
Since the principal role of asbestos in MPM has been sup-
ported by many independent studies we investigated if
TUSC2 expression can be affected by exposure to asbestos.
We found that the TUSC2 expression level was decreased
in both types of tested mesothelial cells upon 24 h of
asbestos exposure, further corroborating the link between
TUSC2 and MPM. Moreover, we showed that a short pre-
treatment of cultured mesothelial cells with ROS scaven-
gers completely abrogated the asbestos effect. This obser-
vation suggests that the suppressive effect of asbestos on
TUSC2 expression is mediated via ROS. Indeed, genera-
tion of ROS by asbestos was documented in many studies
[25]. A yet another source of ROS that may keep the
TUSC2 level down in normal and malignant tissues are
inflammatory cells attracted to the site of asbestos lodging
[31]. We previously showed that TUSC2 is expressed in T-
and B-cells and is involved in the Natural Killer (NK) cells
maturation and function [15]. Therefore, down-regula-
tion of TUSC2 in NK cells and other tumor-infiltrating
lymphocytes by ROS may help cancer cells to escape
immune suppression. Finally, since hypoxia is one of the
most common physiological conditions during tumor
growth we sought evidence of TUSC2 hypoxic link. As a
result, we found in the NCBI Gene Expression Omnibus
several experimental assays performed on different cell
types that consistently showed TUSC2 mRNA suppression
by hypoxia (see records GDS2759, GDS2018, GDS2760,
and GDS2951 for FUS1/TUSC2 at http://
www.ncbi.nlm.nih.gov/sites/entrez). Based on these data
and the dual role of TUSC2 as an immune regulator and
tumor suppressor it may be suggested that TUSC2 sup-
pression during tumor growth may be caused my multiple
factors and in different cells, namely immune cells present
at the site of inflammatory tumor and cancer cells where
the effect of LOH is further aggravated by ROS and
hypoxia (Fig. 5B).
The role of TUSC2 as a tumor suppressor in lung cancer is
widely accepted [16-18]. TUSC2 delivered in lipid-based
nanoparticles drastically reduced the number and size of
human non-small cell lung cancer tumors in mice [19].
The TUSC2 nanoparticles are being tested in a phase 1
safety and dose-escalation clinical trial at the M. D. Ander-
son Cancer Center for patients with advanced non-small
cell lung cancer [32].
To provide insight into the pathways and genes affected
by TUSC2 in MPM, we performed expression microarray
profiling of mesothelioma cells transfected with TUSC2.Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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Table 4: Differentially expressed genes common for TUSC2-expressing MPM cells and clinical tumor specimens.
Fold change and direction in TUSC2-
transfected MPM cells versus control
Fold change and direction in MPM 
versus healthy peritoneum
Gene product name Gene ID
1 -8.04 1.90 ribosomal protein S11 RPS11
2 -4.51 3.50 histone cluster 1, H2ae HIST1H2AE
3 -4.10 3.50 regulator of G-protein signaling 
4
RGS4
4 -3.90 1.80 parathyroid hormone-like 
hormone
PTHLH
5 -3.64 7.00 histone cluster 1, H2bg HIST1H2BG
6 -3.14 2.50 CD24 molecule CD24
7 -3.08 1.40 proteasome (macropain) 
subunit, beta type, 4
PSMB4
8 -2.92 4.80 lysyl oxidase LOX
9 -2.31 2.50 protein phosphatase 1, 
regulatory subunit 15A
PPP1R15A
10 -2.59 2.90 histone cluster 1, H4 h HIST1H4H
11 -2.67 2.87 activating transcription factor 3 ATF3
12 -2.26 1.40 SET translocation 
(myeloid leukemia-associated)
SET
13 -2.22 1.30 histone cluster 2, H2be HIST2H2BE
14 -2.22 4.87 hypothetical protein 
LOC284801
LOC284801
15 -2.21 2.51 transmembrane protein 158 TMEM158
16 -2.18 1.50 histone cluster 2, H2aa3 HIST2H2AA3
17 -2.14 3.75 F-box protein 32 FBXO32
18 -2.12 2.10 histone cluster 1, H3d HIST1H3D
19 -2.12 2.73 SRY (sex determining region Y)-
box 4
SOX4
20 -2.04 1.48 fem-1 homolog b (C. elegans) FEM1B
21 2.02 -1.35 BCL2-like 11 
(apoptosis facilitator)
BCL2L11
22 2.02 -2.10 WD repeat and SOCS box-
containing 1
WSB1
23 2.03 -2.96 chromosome 1 open reading 
frame 21
C1orf21
24 2.04 -1.30 muscleblind-like (Drosophila) MBNL1
25 2.10 -2.20 selenium binding protein 1 SELENBP1
26 2.12 -1.28 butyrophilin, subfamily 3, 
member A1
BTN3A1
27 2.13 -2.20 AF4/FMR2 family, member 4 AFF4
28 2.18 -1.98 transmembrane protein 47 TMEM47
29 2.24 -2.52 superoxide dismutase 2, 
mitochondrial
SOD2
30 2.30 -2.20 SID1 transmembrane family, 
member 2
SIDT2
31 2.35 -1.82 transmembrane and coiled-coil 
domain family 1
TMCC1
32 2.36 -2.52 early growth response 1 EGR1
33 2.40 -2.90 aldehyde dehydrogenase 6 
family, member A1
ALDH6A1
34 2.44 -1.50 cyclin G2 CCNG2
35 2.50 -1.54 cell division cycle 2-like 6 
(CDK8-like)
CDC2L6
36 2.52 -5.20 ribonuclease, RNase A family, 4 RNASE4
37 2.53 -3.80 tensin 1 TNS1
38 2.54 -1.80 myeloid/lymphoid or mixed-
lineage leukemia 5
MLL5
39 2.57 -2.20 forkhead box N3 FOXN3
40 2.75 -3.32 zinc finger E-box binding 
homeobox 1
ZEB1
41 2.76 -2.30 protocadherin 17 PCDH17Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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42 3.06 -9.20 cytochrome P450, family 4, 
subfamily F
CYP4F3
43 3.18 -1.36 complement component 3 C3
44 3.30 -2.03 AT rich interactive domain 5B 
(MRF1-like)
ARID5B
Comparison between expression array data sets reveals 44 concordantly regulated gene
Table 4: Differentially expressed genes common for TUSC2-expressing MPM cells and clinical tumor specimens. (Continued)
Opposite directions of TUSC2 targets modulation in HP2595/TUSC2 versus mesothelioma tumors Figure 4
Opposite directions of TUSC2 targets modulation in HP2595/TUSC2 versus mesothelioma tumors. A. Graph 
shows fold change expression of 44 genes in mesotheliomas as opposed to MPM cells overexpressing TUSC2. Expression 
changes in mesothelioma are shown with red bars while in HP2595 cell line with blue bars. Only statistically significant modula-
tion in mesothelioma as compared to normal peritoneum (p < 0.05) is shown. Gene names that correspond to numbers in the 
bottom are provided in Table 4. B. Representative plots for genes down-regulated in mesothelioma with high p-value, but 
upregulated by TUSC2. C. Representative plots for genes upregulated in mesothelioma with high p-value, but down regulated 
by TUSC2. Each plot shows Affymetrix IDs for each gene probes and respective p-value.Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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As a result, we delineated several groups of genes under
the TUSC2 control. Interestingly, genes involved in chro-
matin modulation, nucleosome assembly and histone
acetylation demonstrated the most robust p-values (0.04
< p < 1.3E-06) indicating that TUSC2 transcriptional
effects are most likely mediated via epigenetic modulation
of chromatin function. In addition, forced expression of
TUSC2 affected genes involved in cell cycle regulation, dif-
ferentiation, and cell growth (0.01 < p < 0.0008) suggest-
ing that TUSC2 possesses principal tumor suppressor
properties. Finally, among newly identified TUSC2 targets
we isolated more than 40 genes that may play important
but not yet established roles in NK, dendritic cells, and T-
and B-lymphocytes activity. Looking for molecular medi-
ators that may be relevant to lupus-like autoimmune phe-
notype observed in our TUSC2 knockout model [15] we
noticed that at least two putative TUSC2 targets, CD24
and CD274/PD-L1/B7-H1 that regulate immunogenic T
and B cells, are linked with systemic autoimmune diseases
such as SLE, MS, and others [33-38]. Based on many stud-
ies, overexpression of CD274 in common cancers helps
tumor progression contributing to evasion from immune
surveillance [39]. Our data suggest that TUSC2 is a potent
suppressor of this key immunoreceptor (Table 3 and Fig.
3). Since blocking of CD274 is now actively pursued as a
novel immunotherapy [40,41], we suggest that TUSC2
may also have important immunotherapeutic implica-
tions.
Our study on the TUSC2 role in mesothelioma underlines
two modes of its biological activity: as a "classical" tumor
suppressor capable of regulating vital cellular processes
such as cell growth, differentiation, and death; and as an
immune system regulator that affects multiple genes
expressed in lymphocyte compartments. Characterization
of a DNA-binding domain in the TUSC2 molecule makes
it possible to further analyze its transcriptional activities
through mutational analysis. The similarity between
TUSC2 and IRF7 is especially important since this IFN-
activated transcriptional factor is a principal component
of the anti-viral response initiated in mitochondria
[42,43]. Since TUSC2 is a mitochondrial protein, our
findings support an important role for mitochondria in
the immune defense against cancer and bring to light pre-
viously unrecognized molecular components of mito-
chondrial immunity.
Conclusion
TUSC2 is a novel tumor suppressor from the critical
3p21.3 chromosomal region frequently deleted in multi-
ple cancers that plays a critical role in lung cancer devel-
opment. While clinical trial on restoration of TUSC2
activities in lung cancer patients is underway, its status
and role in mesothelioma, an aggressive thoracic inflam-
Table 5: TUSC2 modulates 47 genes highly expressed in immune 
cells.
Gene name TUSC2 effect Expression
Profile
1 ADD3 UP III
2 AHSA2 UP III
3 BTN3A1* UP I
4 BTN3A2* UP I
5 BTN3A3* UP I
6 C7orf29* UP I
7 CAST* DOWN I
8 CCDC88A* DOWN I
9 CCNG2 UP III
10 CD274* DOWN I
11 CXCL16 UP II
12 DENND1B* UP I
13 DOCK11* UP I
14 EGR1 UP II
15 ETS1* DOWN I
16 FOXN3 UP III
17 GADD45A DOWN III
18 GADD45B DOWN III
19 HCP5* UP I
20 HIST1H2AE DOWN II
21 HIST1H2BG* DOWN I
22 HIST1H3D* DOWN I
23 HPSE* UP I
24 ICAM1/CD54 UP II
25 IL15* UP I
26 JUN DOWN III
27 LTB* UP IMolecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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matory cancer associated with exposure to asbestos, had
never been established.
We demonstrated earlier that Tusc2-deficient mice display
a complex immuno-inflammatory phenotype with a pre-
disposition to cancer. The data presented here provide the
first evidence that the TUSC2 protein plays an essential
tumor suppressive role in asbestos-induced mesotheli-
oma. This conclusion is supported by the decreased
TUSC2 levels in the majority of MPM specimens and
down-regulation of TUSC2 expression by asbestos-gener-
ated reactive oxygen species (ROS). On the molecular
level, we associated TUSC2 with activation of multiple
tumor-suppressor genes, down-regulation of oncogenes,
and modulation of numerous immune genes. Overall,
our study suggests that restoration of TUSC2 activities in
MPM patients may have important therapeutic implica-
tions.
Methods
Mesothelioma specimens and RNA isolation
All patients gave informed consent for de-identified use of
tissues under the Wayne State University IRB approved tis-
sue consent document D1420: Collection of Serum and
Tissue Samples for Patient's with Biopsy Proven or Sus-
pected Malignant Disease. Immediately after surgical
resection tissues were snap frozen and kept at -80°C until
RNA isolation. For RT-PCR assessment of TUSC2 expres-
sion we used tumor/control matched specimens derived
from thirty MPM patients. Control specimens were
derived from unaffected peritoneum. RNA from these
specimens was extracted using MirVana kit (Applied Bio-
systems, Foster City, CA) for subsequent TUSC2 RT-PCR
analyses.
TMA slides
Immunohistochemical analysis was performed using two
sources of multi-tissue pleural mesothelioma arrays
(TMA). Three TMAs were made using MPM samples
obtained from patients at Karmanos Cancer Institute
(Detroit, MI). They contained a total of 30 cases repre-
sented by 2-mm cores of resected tumors and adjacent
mesothelial tissues. A validating set of four TMA slides
containing 75 MPM cases from the MD Anderson Cancer
Center (Houston, TX) were constructed using triplicate 1
mm diameter cores from each tumor. All patients gave
informed consent for de-identified use of tissues. Both
studies were approved by the Wayne State University and
The University of Texas IRB Institutional Review Boards.
Immunohistochemical staining
Rabbit anti-TUSC2 polyclonal antibodies used for immu-
nohistochemical staining were raised against a synthetic
oligopeptide derived from NH2-terminal amino acid
sequence (NH2-GASGSKARGLWPFAAC) [16]. Formalin-
fixed and paraffin-embedded tissue histology sections (5
μm thick) were deparaffinized, hydrated, and heated in a
steamer for 10 min. with 10 mmol/L of sodium citrate
(pH 6.0) for antigen retrieval. Peroxide blocking was done
with 3% H2O2 in methanol at room temperature for 15
min, followed by 10% bovine serum albumin in TBS-t for
30 min. The slides were incubated with primary antibody
at a 1:400 dilution for 65 min at room temperature. After
28 MALAT1* DOWN I
29 MBNL* UP I
30 METTL4* UP I
31 MIB1 UP II
32 MLL5 UP III
33 NT5E DOWN II
34 PARP9* UP I
35 PLAUR DOWN III
36 PPP1R15A* DOWN II
37 PSMB9* UP I
37 RGS2* DOWN I
39 SELENBP1 UP II
40 SNX5 DOWN III
41 SOX4* DOWN I
42 TncRNA DOWN II
43 TNRC6B UP III
44 TNS1* UP I
45 UBE2L6* UP I
46 ZNF224* UP I
47 ZNF652 UP II
Profile I - genes expressed exclusively in immune cells; Profile II- 
genes expressed mainly in immune cells; Profile III - widely expressed 
genes that show highest expression levels in the immune 
compartments. Expression profiling was performed via http://
biogps.gnf.org.
Table 5: TUSC2 modulates 47 genes highly expressed in immune 
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washing with PBS, incubation with biotin-labeled second-
ary antibody for 30 min followed. Finally, the samples
were incubated with a 1:40 solution of streptavidin-perox-
idase for 30 min. The staining was then developed with
0.05% 3',3-diaminobenzidine tetrahydrochloride pre-
pared in 0.05 mol/L of Tris buffer at pH 7.6 containing
0.024% H2O2 and then counterstained with hematoxylin.
Normal mesothelial tissue was used as a positive control.
For a negative control, we used the same specimens used
for the positive controls, replacing the primary antibody
with PBS.
Subcellular and tissue distribution of the TUSC2 protein
TUSC2 immunostaining was detected in the cytoplasm of
mesothelial and tumor cells (Fig. 1). Immunohistochem-
ical expression was quantified in a blinded fashion by two
independent pathologists (LP and DN) using a four-value
intensity score (0, 1+, 2+, and 3+) and the percentage of
the reactivity. A consensus value on both intensity and
reactivity was reached by the two independent observers.
A final consensual score was obtained by multiplying
both intensity and extent of reactivity values (range, 0-
300), and four levels of staining were calculated based on
that score: (a) negative (score 0), (b) low (score ≤ 100), (c)
intermediate (score > 100 to ≤ 220), and (d) and high
(score > 220) expressions.
ROMA and data processing
Since FUS1 has been previously associated with the
3p21.3 deletion in lung and other cancers [10], we used
our previously produced Representational Oligonucle-
otide Microarray Analysis (ROMA) data [23] for assess-
ment of this association in MPM specimens. ROMA, as
compared to other array comparative genomic hybridiza-
tion (aCGH) technologies, is better suited for transla-
tional research due to its higher sensitivity [44]. The arrays
used for the ROMA analyses and data processing were
described previously [44]. Briefly, for ROMA analysis, 27
snap-frozen specimens (22 tumor and 5 normal) derived
from 22 patients with MPM were used to produce 27 DNA
samples. 4 out of 5 normal samples were tumor-matched.
DNA from snap-frozen tissues was isolated with QIAamp
mini-kit (Qiagen, Valencia, CA) and assayed for concen-
tration and quality using Victor3 microplate reader (Perk-
Molecular and biological properties of TUSC2 Figure 5
Molecular and biological properties of TUSC2. A. Similarity with the interferon regulatory factor IRF7 suggests DNA-
binding property for TUSC2. N-terminus of TUSC2 shows ~40% identity with the IRF7 segment that contains a DNA-binding 
site (framed). Histogram shows positions conserved in the IRF protein family. The arginine residue (R) conserved throughout 
the IRF protein family is marked with asterisk. B. Different mechanisms of TUSC2 down-regulation in tumor and immune cells. 
Modulation of TUSC2 in tumor and host immune cellular compartments may contribute to tumor growth via blocking TUSC2 
tumor suppressive or immune-regulatory properties.Molecular Cancer 2009, 8:91 http://www.molecular-cancer.com/content/8/1/91
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inElmer, Waltham, MA). Matching detailed clinical
information for these specimens was available.
Cell lines
SV40-transfected mesothelial cell line Met5A, primary
pleural mesothelial cultured cells and H2595 epithelial
MPM cells lines were grown in 1× DMEM supplemented
with sodium pyruvate, high glucose and 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA). The H2595 cell
line was established in our laboratory from a surgical
specimen obtained by one of the authors (HP) [26].
Asbestos and reactive oxygen species (ROS) experiments
We treated Met5A and primary pleural mesothelial cells
with 2.5 μg/cm2 of crocidolite asbestos for 24 hours. Pre-
treatment of the cells with 500 U/ml catalase (a specific
H2O2 scavenger) or 250 U/ml superoxide dismutase SOD
(a specific superoxide anion O2
- scavenger) was done for
30 min. prior to addition of asbestos. Both experiments
were performed in triplicates and repeated twice.
TUSC2 overexpressing constructs and transfection
The open reading frame (ORF) for forced expression of
human TUSC2 was obtained by RT-PCR on human RNA.
The amplified product was cloned in a polylinker-con-
taining vector, excised with EcoRI and BamI, and sub-
cloned into pCMV2/FLAG (Sigma-Aldrich, St. Louis,
MO). Genes integrated in this vector are controlled by the
CMV promoter. Sequence fidelity and accurate reading
frame were verified by DNA sequencing. All cells in the
study were transfected using Lipofectamin2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer's protocol.
Gene expression profiling and Xenobase analysis
Total RNA from TUSC2-transfected and vector-transfected
MPM H2595 cell line were isolated with Qiagen RNeasy
kit, analyzed for quality using an Agilent Bioanalyzer and
hybridized with the Affymetrix U133 2.0 Plus microarray.
Gene expression data were analyzed using Xenobase, a
databank and software designed for translational studies
in the Van Andel Research Institute (Grand Rapids, MI,
[27]). Along with the in vitro cell line microarray data, we
included into the analysis an Affymetrix U133 2.0 Plus
data set previously obtained by us on thirty other MPM
tumor specimens compared with normal peritoneum (n =
7) [23]. Profiling of Affymetrix data to identify statistically
significant biological groups of genes was done using
Xenobase software for hypergeometric analysis of gene
annotations provided by the Gene Ontology Program
http://www.geneontology.org.
RT-PCR analysis
Reverse transcription - polymerase chain reaction (RT-
PCR) was done using Super Script One-Step RT-PCR kit
(Invitrogen, Carlsbad, CA). Primers for RT-PCR assess-
ment of gene expression were designed as described [45].
Conditions for the reaction were as follows: 50°C - 30
min., 35 cycles of (94°C - 15 sec, 56°C - 15 sec, 72°C - 1
min.), 72°C - 5 min. Oligonucleotide sequences for RT-
PCR were designed as follows: LTB: 5'-ATCACTGTCCT-
GGCTGTGCT-3', 5'-GCAGCACTGAAGCTTTCCAT-3'; FU
S1 (TUSC2): 5'-AACTCCCAGGCTCAATCAAG-3' -, 5'-CA
GACTCTGCCACGACATC-3';  MALAT1: 5'-GAAGGTCT-
GAAGCTCATACC-3', 5'-CTTTCCATTACGCAACTGAG-3';
MIHG1: 5'-ATGTTTTGCCACGTGGATGT-3', 5'-GGCAAT-
CATAACCAACCATC-3'; CCNG2: 5'-TTGTTGAACGTC-
TACCTGGA-3', 5'-CACTCTTGATCACTGGGAG-3'; LOX:
5'-GAGAAGTTCCTGCGCTCAGT-3', 5'-ACCAGGCACT-
GATTTATCCA-3'. RT-PCR with primers to invariantly
expressed PPIA (5'-TCTGAGCACTGGAGAGAAAGG-3',
5'-GGAAAACATGGAACCCAAAGG-3') was used as a
loading control. Band intensities were measured using
Kodak 4000 Image Station. Repeated experiments showed
consistency of our RT-PCR analysis.
Statistical evaluation
Results are expressed as percentages or medians and
ranges. Statistical analysis included two sided Student's t-
test reported as mean standard error. Statistical signifi-
cance was considered at p < 0.05.
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